^
    1year
    The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling. (PubMed, Lung Cancer)
    In conclusion, MD simulations can effectively predict patient outcomes by connecting computational results with clinical data and advancing our understanding of EGFR mutations and their therapeutic responses.
    Journal • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR A763_Y764insFQEA • EGFR exon 20 mutation • EGFR A767_V769dup • EGFR S768_D770dup
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • Zegfrovy (sunvozertinib) • zipalertinib (CLN-081)
    almost2years
    First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review. (PubMed, Medicine (Baltimore))
    The present study indicates that furmonertinib may be a first-line treatment option for patients with non-small cell lung cancer harboring EGFR ex20ins mutation.
    Review • Journal • EGFR exon 20 • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR N771_P772insVal • EGFR S768_D770dup • EGFR S768_D770dupSVD
    |
    pemetrexed • Ivesa (firmonertinib)
    2years
    Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non-small cell lung cancer. (PubMed, Thorac Cancer)
    A new modality of treatment for NSCLC patients with EGFRx20ins has been established with the approval of mobocertinib and amivantamab. There are also numerous novel targeted treatments for NSCLC with EGFRex20ins in development, which are anticipated to improve this patient population's survival even further. This review provides a reference for the clinical management of these patients by summarizing the most recent epidemiological, and clinicopathological characteristics, diagnostic techniques, and therapeutic advances of EGFRex20ins in NSCLC.
    Review • Journal • IO biomarker • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR positive • EGFR A767_V769dup • EGFR S768_D770dup
    |
    Rybrevant (amivantamab-vmjw) • Exkivity (mobocertinib)
    2years
    An in vitro model and the underlying pathways of sinonasal inverted papilloma development. (PubMed, Sci Rep)
    These results suggest that specific mutations in EGFR exon 20 play a crucial role in SIP development, partially though hyper-activation of the PI3K/AKT and MAPK signaling pathways. This study presents the first in vitro model for SIP development, which could facilitate further investigations into SIP pathogenesis and preclinical studies for new therapeutic agents.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR expression • EGFR exon 19 mutation • EGFR exon 20 mutation • EGFR E746 • EGFR S768_D770dup
    over2years
    Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins) (IASLC-WCLC 2023)
    First line with Afatinib 40mg QD from 8/30/2018 to 2/13/2019...On May 19, 2022, a new line of treatment begins with Carboplatin plus Pemetrexed every 3 weeks for 4 cycles and then maintenance with Pemetrexed until present, with good tolerance and clinical benefit. This case report confirms the efficacy of second-line treatment with Amivantamab in EGFR ex20insertion NSCLC, even at the level of brain lesions. The treatment resulted in a prolonged survival with a good quality of life for the patient.
    EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR amplification • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR S768_D770dup
    |
    Gilotrif (afatinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)
    over2years
    EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy (IASLC-WCLC 2023)
    This study investigated the distribution of EGFR E20ins in the Asian population, with p.A767_V769dup and p.S768_D770dup being the most frequently observed mutations. Since some studies have reported single EGFR E20ins sequences using different names, it is important to be cautious when describing EGFR E20ins. To ensure comprehensive coverage in real-world settings, each method used for the detection of EGFR E20ins must be annotated according to the HGVS nomenclature.
    EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR A767_V769dup • EGFR S768_D770dup
    |
    cobas® EGFR Mutation Test v2 • Oncomine™ Dx Target Test • Droplex EGFR Mutation Test v2 • GenesWell ddEGFR Mutation Test
    over2years
    Clinical efficacy analysis of furmonertinib and structural insights into sensitivity to diverse TKIs for NSCLC with EGFR exon 20 insertion. (ASCO 2023)
    Furthermore, rather than erlotinib (GlideScore: -5.564; MM/GBSA: -52.8044), gefitinib (-7.68; -47.317), and afatinib (-5.075; -44.64), furmonertinib (-11.085; -68.1575) and osimertinib (-10.031; -63.87) revealed favorable binding activity to EGFRex20ins, with furmonertinib being the most significant. Furmonertinib might have positive clinical efficacy to advanced NSCLC pts with EGFRex20ins on account of its favorable binding activity to EGFRex20ins. It may be the optimal choice for these pts in the future.
    Clinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR S768_D770dup
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Ivesa (firmonertinib)
    over2years
    A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. (PubMed, J Cancer Res Clin Oncol)
    Furmonertinib has shown encouraging antitumor activity and CNS activity in patients with advanced NSCLC with EGFR ex20ins. Moreover, furmonertinib had a good safety profile and no dose-dependent toxicity.
    Journal • Real-world evidence • EGFR exon 20 • Real-world
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR A767_V769dup • EGFR S768_D770dup
    |
    Ivesa (firmonertinib)
    almost3years
    Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR Exon 20 insertion (ELCC 2023)
    Furthermore, rather than erlotinib (GlideScore: −5.564; MM/GBSA: −52.8044), gefitinib (−7.68; −47.317), and afatinib (−5.075; −44.64), furmonertinib (−11.085; −68.1575) and osimertinib (−10.031; −63.87) revealed favorable binding activity to EGFRex20ins, with furmonertinib being the most significant. Conclusions Furmonertinib has positive clinical efficacy to advanced NSCLC pts with EGFRex20ins probably based on its favorable binding activity to EGFRex20ins. Furmonertinib may be the optimal choice for these pts in the future.
    Clinical • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR S768_D770dup
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Ivesa (firmonertinib)
    almost3years
    Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation (ESMO-TAT 2023)
    Furthermore, rather than erlotinib (GlideScore: -5.564; MM/GBSA: -52.8044), gefitinib (-7.68; -47.317), and afatinib (-5.075; -44.64), furmonertinib (-11.085; -68.1575) and osimertinib (-10.031; -63.87) revealed favorable binding activity to EGFRex20ins, with furmonertinib being the most significant. Conclusions Furmonertinib has positive clinical efficacy to advanced NSCLC pts with EGFRex20ins probably based on its favorable binding activity to EGFRex20ins. Furmonertinib may be the optimal choice for these pts in the future.
    Clinical • EGFR exon 20 • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR S768_D770dup
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Ivesa (firmonertinib)
    over3years
    Amivantamab vs real-world (RW) therapies for advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (E20i) in Japan (ESMO 2022)
    Here we also explore amivantamab versus docetaxel (DOC), EGFR tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO) in RW practice in Japan using a lung cancer genomic screening platform (LC-SCRUM-Asia) with more than 16,000 NSCLC pts from 2013. Conclusions Amivantamab-treated pts had better clinical benefits compared to DOC, TKIs and IO. Amivantamab should be considered a standard therapy after platinum-based chemotherapy for EGFR E20i aNSCLC pts.
    Clinical • Real-world evidence • IO biomarker • EGFR exon 20
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR A767_V769dup • EGFR S768_D770dup
    |
    docetaxel • Rybrevant (amivantamab-vmjw)